Alexander Davidson is testing a nerve-connected LUKE Arm at home for a year, extending Utah’s neuroprosthetics research into unsupervised everyday use.

Neuralink is using 50,000 hours of intracortical data to pretrain BCI models that reduce recalibration while improving day-to-day cursor control.

Newronika has begun a 104-patient pivotal trial of αDBS, comparing adaptive and conventional stimulation as it advances its US approval pathway.

Europe’s neurotech ecosystem is expanding as EBC, new funding programmes and Brain Innovation Days push research toward responsible scale and adoption.

Neurable launches its first standalone EEG headphones as consumer EEG moves toward familiar wearables, personal baselines, and longer-term tracking.

Clarity reports early Alzheimer’s data showing 40 Hz neural entrainment and an exploratory memory signal from its VR-based stimulation platform.

Theranica used data from 53,065 Nerivio users to predict next-day migraine risk, adding a forecasting layer to its neuromodulation platform.

China expands its BCI standards framework as funding reaches IPO candidates, established clinical platforms, and a growing group of ultrasound companies.

Precision Neuroscience raises $250m as Layer 7 advances through clinical validation toward commercialization and a fully implantable BCI for paralysis.

TBC is bringing a neuron-derived AI optimisation model to AWS, pairing lower inference costs and faster video generation with existing cloud workflows.

ReEmerge raises $37M to advance CNRT, a patient-specific thalamic DBS approach for chronic cognitive impairment after traumatic brain injury.

Salvia is testing an implantable neuromodulation system for treatment-resistant migraine, with trials underway in the US, Europe and Australia.

Apple’s Sonera acquisition adds magnetic sensing to a growing biosignals portfolio spanning wearables, gesture control, and neurotechnology.

Nyxoah reports new U.S. clinical milestones for Genio as it seeks a broader label and expands its commercial footprint in sleep apnea treatment.

South Korea is coordinating BCI research, industry and clinical infrastructure as domestic implants and bidirectional systems move toward trials.

EEG recordings can retain person-specific signatures after de-identification, prompting researchers to develop stronger privacy-preserving methods.

Brain foundation models aim to generalize EEG across people, devices and tasks. Arctop and Piramidal discuss scale, representation and real-world deployment.

Fareon’s first-in-human MMT study links treatment response to blood protein changes, adding systemic biomarker data to its early Long COVID program.

BrainScope reports an EEG biomarker for earlier dementia risk, extending a five-channel frontal EEG platform already used in traumatic brain injury.

ONWARD has begun a mobility study of ARC-IM as spinal cord stimulation expands from chronic pain into restorative neurotechnology after SCI.

Google maps the complete male fruit fly nervous system, extending a decade-long connectomics effort as network mapping finds wider applications.

Atlas opens pre-orders for a behind-the-ear EEG wearable, testing whether continuous brain tracking can earn a place in everyday consumer wearables.

CorTec receives a second FDA Breakthrough designation as Brain Interchange expands from stroke rehabilitation into assistive computer control.

Meta’s Neural Band brings wrist-based EMG control to smart glasses just as the platform it controls faces growing scrutiny over discreet recording.

Empatica has received FDA clearance for Parkinson’s monitoring, bringing PKG’s established motor-tracking algorithms onto its wearable platform.

California’s AB 1883 would restrict workplace neural data collection and emotional-state inference, extending neurotech rules beyond privacy alone.

Vielight is moving photobiomodulation from consumer wellness into larger clinical studies, including a $4.6M DoD-funded trial in persistent mild TBI.

Ceribell expands its point-of-care EEG platform with new FDA clearances, delirium reimbursement, and a growing push into bedside brain monitoring.

Samsung and UCSF Neuroscape will test whether Galaxy Watch biometrics can track cognitive change, as wearables move toward brain-health inference.

Aleph Neuro is developing functional ultrasound for non-invasive brain decoding, joining a wider group of companies building around the modality.

INBRAIN's CEO Carolina Aguilar describes advancing a graphene neural interface from first-in-human testing toward Parkinson’s therapy, combining decoding, stimulation and AI.

BrainsWay and electroCore stand out in a weak year for public neurotech, with strong Q2 revenue growth adding to substantial 2026 share-price gains.

Boston Scientific is expanding neurotech through acquisitions, while Medtronic mixes buyouts, partnerships and investments around an existing portfolio.

Universal Brain’s FDA cleared EEG system adds objective monitoring to psychiatry while pointing toward longer-term treatment-response prediction.

Epitel has raised $26m to expand REMI, a wearable EEG platform designed to extend seizure monitoring across hospitals, homes, and younger patients.

Neurofounders tested Mendi’s fNIRS headband to assess its at-home training experience, underlying science, and place in consumer neurofeedback.

Temple is shifting its wearable patch toward Entropy, a metabolic metric that places it closer to the wider wearables market than the brain.

Precision Neuroscience’s Jayme Strauss explains how Layer 7, hospital integration and clinical data are shaping its path towards an implantable BCI.

The Global Brain Capital Index broadens economic measurement to include brain health, cognitive skills, creativity and the conditions that support them.

Preventative scanning is moving into wellness, with MYndspan and Connectome adapting MEG and fNIRS for repeatable, non-diagnostic brain assessments.

Consumer EEG is expanding across sleep, cognition, and device control, but wider adoption will depend on integration into familiar everyday hardware.

Cortical Labs is widening access to biological computing, betting broader experimentation will uncover viable uses before the field settles its terms.

Fluent has raised A$2m to develop a subscalp EEG speech interface, with first-in-human studies planned as it tests a less invasive decoding route.

Neuralink completed its first transdural N1 implant, removing a manual dural incision while retaining the craniotomy and wider risks of brain surgery.

Cognito CEO Christian Howell discusses the HOPE trial, the evidence behind 40 Hz sensory stimulation, and the challenge of scaling Alzheimer’s care.

Apple is standardising how neurotech connects to its devices while adding more native health features, raising questions over where its role ends.

Meta’s Brain2Qwerty v2 lifts non-invasive brain-to-text accuracy to 61% from MEG, but bulky scanners and offline decoding still block practical use.

Gestala has raised RMB 570M within six months of launch, and is now expanding its ultrasound BCI platform across Chengdu and Shanghai.

Somareality raised €3M+ to move eye-tracking biomarkers from enterprise settings into cognitive wellness, where signal quality, validation, and platform control remain central questions.

EEG foundation models mark a shift from task-specific classifiers toward reusable neural encoders, with in-ear EEG emerging as one route to real-world brain data.

Clair Health is building a wrist-worn wearable that infers hormone patterns from physiological signals. Its challenge is proving proxy data can support clinically useful hormone intelligence.

Flourish has raised $500M to build Cortex AI, a brain-inspired system targeting lower-power AI compute. The company enters a crowded biomimetic field without product data or benchmarks.

UNEEG’s FDA clearance brings EpiSight into the US, adding a second implantable continuous EEG system for epilepsy and highlighting the shift from patient logs to longitudinal seizure data.

Samsung’s reported Neuralink chip order connects the BCI company’s next implant generation to a wider Musk manufacturing push across semiconductors, Austin production, and future scale.

Paradromics has implanted Connexus in the first participant in its early feasibility study, testing whether high-bandwidth intracortical BCI can support speech restoration and computer control over time.

Wave Neuroscience has received FDA clearance for MeRT, an EEG-guided TMS system for PTSD. The decision adds to a growing regulatory opening for neuromodulation in psychiatric care.

ABILITY Neurotech’s first ALS study will test an ECoG BCI built around broad cortical coverage, optical data transfer, speech decoding, computer control, and home use.

Oculogica’s SNAP clearance moves eye-tracking concussion assessment into faster sideline workflows, while its age label keeps the first market focused on high school and college sports.

Brain-sensing earbuds are moving productivity tools from subjective focus tracking toward contextual cognitive-state data, with EEG earbuds tracking longitudinal data and providing key focus metrics.

Neuracle and BrainCo are moving toward public listings as Chinese BCI funding accelerates, with large rounds, state backing and different routes into medical, assistive and consumer neurotech markets.

ShiraTronics has completed enrollment in RELIEV-CM2, a pivotal study of its implantable migraine neurostimulator, as regulatory and coding steps begin to shape its path toward FDA review.

Omniscient’s Series D pairs Quicktome expansion with a new CPT code for connectomic analysis, as brain mapping moves from surgical planning tool toward reimbursable clinical workflow.

Pulsetto’s Hackney Half project shows how consumer neurotech is entering running recovery, using VNS, wearables, and case-based data to frame nervous system regulation as a performance layer.

Oura is pairing ring data with cognitive testing and sleep-care pathways, pointing to a clinical-adjacent model built around proxy signals rather than direct neural measurement.

Kariya and NeuraLight are pairing a brain-penetrant GLP-1 program with vision-based biomarkers, as neurodegeneration trials look for better ways to measure functional change.

EEG earbuds are moving sleep monitoring closer to direct brain measurement, using in-ear signals to capture sleep architecture and support adaptive audio intervention across home and research use.

Prophetic has introduced ultrasound headbands for lucid dreaming, moving an old consumer neurotech idea into focused ultrasound while leaving efficacy and sleep-safety questions unresolved.

Neurovalens received FDA De Novo approval for Modius Spero in PTSD, extending its Modius platform to a fourth indication and strengthening the company’s broader vestibular stimulation thesis.

AMPA’s financing points to a wider shift in MDD neuromodulation, as portable TMS, home-use devices, accelerated protocols, and broader labels begin to reshape how treatment reaches patients.

Oman’s Neuralink investment adds to Gulf activity around BCI, from QIA’s stakes in Neuralink and Synchron to NEOM’s Paradromics center. The pattern links capital, clinics, and regional positioning.

Neurosoft raised a $7.5M seed round to advance soft cortical BCIs, pairing Swiss neuroengineering roots with US investors, clinical trials, and Science Corp’s BCI infrastructure.

SonoMind raised €20 million to advance a focused ultrasound treatment for depression, testing whether non-invasive deep brain targeting can become a clinical option for treatment-resistant patients.

Consumer neural sensing is entering through device control, from gestures and jaw activity to silent speech. In-ear EEG adds a deeper layer by linking those interaction to cognitive state.

Neural Galaxy’s MRI-guided TMS study points to a more precise neurotech approach to ASD, while raising harder questions around core symptoms, pediatric consent, and identity.

Harris Eyre explains how the brain economy frames brain health and cognitive skills as economic infrastructure, with new metrics, policy models, and funding tools moving the field toward implementation.

FinalSpark and Cortical Labs show biocomputing moving from lab concept to early access platforms, with current use still shaped by control, interpretation, scalability, and ethics.

France’s neurotech ecosystem is taking shape across EEG, ultrasound, stimulation, stroke tools, and brain-data infrastructure, supported by research institutions and a record of early acquisitions.

Motif’s FDA IDE moves its depression implant into first clinical testing, while its MintNeuro partnership highlights the chip-level constraints behind smaller therapeutic BCIs.

Europe’s first Brain Economy Summit framed brain capital as an economic asset. The harder question is whether Europe can turn neuroscience, policy, and funding into scalable systems.

Brain-on-chip systems are moving from lab models toward preclinical infrastructure, using human neural circuits to test drug effects, toxicity, and disease-relevant responses before clinical trials.

Axoft’s $55M Series A highlights a growing focus on implant materials in BCI, as companies work to improve tissue compatibility, signal quality, and the durability needed for clinical translation.

TBC is using living neuronal networks to derive software adapters for AI models, positioning biological computing as an emerging infrastructure layer rather than a purely research tool.

Sabi has emerged from stealth with a claimed thought-to-text EEG beanie, testing whether high-density sensors and AI can push consumer neurotech beyond metrics and into usable neural input.

April brought a cluster of neural interface updates across cortical, spinal, endovascular, peripheral, and materials-led systems, showing progress beyond a single BCI product model.

INBRAIN has completed enrolment in its first human graphene cortical interface study, adding safety and signal-quality data to its broader push around materials-led BCI development.

Synchron’s INTENT trial marks a new stage in its clinical translation, as the company pairs endovascular BCI development with reimbursement, software, and platform integration work.

CFG’s new white paper signals a more coordinated EU approach to neurotechnology, centered on funding gaps, regulatory clarity, and the unresolved boundary between wellness and medicine.

Synchron’s Kurt Haggstrom discusses BCI commercialization, reimbursement, competition, and why minimally invasive implants may matter more than headline-driven narratives.

Inner Cosmos is developing an implanted neurostimulation system for treatment-resistant depression, reflecting a shift toward more continuous, home-based psychiatric care.

WHOOP and Oura are moving closer to brain-adjacent insights, but not through direct readings. Both are doubling down on proxy signals, AI, and trusted form factors.

Epia Neuro has emerged from stealth with a minimally invasive BCI for stroke recovery. Its launch adds to a more active BCI market, where capital and competitive pressure are both rising.

Rune Labs has launched a Parkinson’s AI companion built on years of wearable-derived patient data. The move highlights how cleared neurotech tools can turn clinical monitoring into a longer-term data advantage.

Theta Neuro has raised a $2m pre-seed to advance a wearable EEG patch for seizure prediction. The broader question is whether non-invasive forecasting can become a credible epilepsy product category.

India’s neurotech sector is becoming more active across wearables, neuromodulation, biosignal tooling, and computational diagnostics. The ecosystem is broadening, though still early and uneven.

Neurotechnology is starting to enter addiction care through withdrawal support, cue-reactivity assessment, and digital biomarkers. But most approaches remain early and difficult to scale.

Neurable used EEG-enabled hearing protection to record brain activity during live breaching drills. The dataset points to short-window neural changes that standard post-event assessment can miss.

Cognito’s Ochsner deal sits further along a broader shift in neurotech partnerships, from invasive research sites to translational collaborators and now care-system integration.

Synaptrix is showing that better models, data, and hardware integration can push non-invasive BCI further. Aryan Govil outlines why the company starts with wheelchair control.

The Declaration of Sydney outlines an ethical framework for computational neurosurgery, with wider implications for oversight, enhancement, and neurotech governance.

Neurotech is attracting more candidates, but hiring remains narrow and specialised. Chay Carter explains where talent gaps persist and how candidates can position themselves more realistically.